CN103906530B - 成纤维细胞生长因子21变体 - Google Patents
成纤维细胞生长因子21变体 Download PDFInfo
- Publication number
- CN103906530B CN103906530B CN201280048530.2A CN201280048530A CN103906530B CN 103906530 B CN103906530 B CN 103906530B CN 201280048530 A CN201280048530 A CN 201280048530A CN 103906530 B CN103906530 B CN 103906530B
- Authority
- CN
- China
- Prior art keywords
- fgf21
- variant
- seq
- variants
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542906P | 2011-10-04 | 2011-10-04 | |
| US61/542,906 | 2011-10-04 | ||
| PCT/US2012/057053 WO2013052311A1 (en) | 2011-10-04 | 2012-09-25 | Fibroblast growth factor 21 variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103906530A CN103906530A (zh) | 2014-07-02 |
| CN103906530B true CN103906530B (zh) | 2016-01-20 |
Family
ID=46964112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280048530.2A Expired - Fee Related CN103906530B (zh) | 2011-10-04 | 2012-09-25 | 成纤维细胞生长因子21变体 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8541369B2 (enExample) |
| EP (1) | EP2763689B1 (enExample) |
| JP (1) | JP6060167B2 (enExample) |
| KR (1) | KR20140059271A (enExample) |
| CN (1) | CN103906530B (enExample) |
| AP (1) | AP2014007532A0 (enExample) |
| AR (1) | AR087973A1 (enExample) |
| AU (1) | AU2012318956A1 (enExample) |
| BR (1) | BR112014007532A2 (enExample) |
| CA (1) | CA2843520A1 (enExample) |
| CL (1) | CL2014000801A1 (enExample) |
| CO (1) | CO6910165A2 (enExample) |
| CR (1) | CR20140142A (enExample) |
| DO (1) | DOP2014000050A (enExample) |
| EA (1) | EA201490521A1 (enExample) |
| EC (1) | ECSP14013285A (enExample) |
| ES (1) | ES2548214T3 (enExample) |
| IL (1) | IL230754A0 (enExample) |
| IN (1) | IN2014CN00782A (enExample) |
| MA (1) | MA35458B1 (enExample) |
| MX (1) | MX2014004159A (enExample) |
| PE (1) | PE20142044A1 (enExample) |
| PH (1) | PH12014500740A1 (enExample) |
| SG (1) | SG11201401792UA (enExample) |
| TN (1) | TN2014000096A1 (enExample) |
| TW (1) | TWI461435B (enExample) |
| WO (1) | WO2013052311A1 (enExample) |
| ZA (1) | ZA201400882B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2068909T3 (pl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modyfikowane polipeptydy fgf-21 i ich zastosowanie |
| PL2726511T3 (pl) | 2011-07-01 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych |
| HK1202800A1 (en) * | 2012-05-15 | 2015-10-09 | Eli Lilly And Company | Therapeutic uses of fibroblast growth factor 21 proteins |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| KR20150006059A (ko) * | 2012-06-11 | 2015-01-15 | 일라이 릴리 앤드 캄파니 | 섬유모세포 성장 인자 21 변이체 |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| SG11201504815QA (en) | 2012-12-27 | 2015-07-30 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| NZ718962A (en) | 2013-10-28 | 2019-12-20 | Ngm Biopharmaceuticals Inc | Cancer models and associated methods |
| AU2015209131B2 (en) | 2014-01-24 | 2020-06-25 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| WO2015138278A1 (en) * | 2014-03-11 | 2015-09-17 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| EP3155005A4 (en) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CN114129709A (zh) | 2014-10-23 | 2022-03-04 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| CA3003616C (en) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| WO2017220706A1 (en) * | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Pharmaceutical compositions of fgf21 derivatives and uses thereof |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN106220724B (zh) * | 2016-09-13 | 2019-10-11 | 河南师范大学 | 人成纤维细胞生长因子21重组蛋白及其制备方法和应用 |
| CN106397607A (zh) * | 2016-09-13 | 2017-02-15 | 河南师范大学 | 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用 |
| CN106432509B (zh) * | 2016-09-13 | 2019-05-21 | 河南师范大学 | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 |
| CN108570109B (zh) | 2017-03-14 | 2022-04-26 | 广东东阳光药业有限公司 | 包含免疫球蛋白Fc部分的双靶点融合蛋白 |
| CN111050786A (zh) | 2017-09-08 | 2020-04-21 | 百时美施贵宝公司 | 用于治疗非酒精性脂肪性肝炎(nash)的方法的修饰的成纤维细胞生长因子21(fgf-21) |
| IL275499B2 (en) | 2017-12-22 | 2024-03-01 | Novartis Ag | Methods of treating metabolic disorders with fgf21 variants |
| AU2019218147B2 (en) * | 2018-02-08 | 2023-06-08 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
| US12226451B2 (en) | 2018-07-03 | 2025-02-18 | Bristol-Myers Squibb Company | FGF-21 formulations |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| EP3935075A4 (en) * | 2019-03-05 | 2023-01-18 | Sunshine Lake Pharma Co., Ltd. | POLYPEPTIDE MOLECULE AND APPLICATION THEREOF |
| CN111944055B (zh) | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| WO2021142143A1 (en) | 2020-01-08 | 2021-07-15 | Bristol-Myers Squibb Company | Fgf-21 conjugate formulations |
| CN115322794B (zh) | 2020-01-11 | 2025-09-19 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| EP4192495A1 (en) | 2020-08-07 | 2023-06-14 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| KR102495299B1 (ko) * | 2020-11-03 | 2023-02-06 | 토드제약 주식회사 | Fgf21의 열탄력성을 이용한 fgf21 생산 방법 |
| WO2022115597A1 (en) | 2020-11-25 | 2022-06-02 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| CA3224743A1 (en) | 2021-07-14 | 2023-01-19 | Beijing Ql Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1890371A (zh) * | 2003-12-10 | 2007-01-03 | 伊莱利利公司 | 成纤维细胞生长因子的21突变蛋白 |
| CN101010338A (zh) * | 2004-09-02 | 2007-08-01 | 伊莱利利公司 | 成纤维细胞生长因子21的突变蛋白 |
| WO2010065439A1 (en) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| CN102143758A (zh) * | 2008-06-04 | 2011-08-03 | 安姆根有限公司 | Fgf21突变体及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| WO2006028714A1 (en) | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| PL2068909T3 (pl) | 2007-03-30 | 2012-09-28 | Ambrx Inc | Modyfikowane polipeptydy fgf-21 i ich zastosowanie |
| US20120052069A1 (en) | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| SMT202400036T1 (it) | 2009-05-05 | 2024-03-13 | Amgen Inc | Mutanti fgf21 e loro utilizzi |
-
2012
- 2012-09-20 AR ARP120103466A patent/AR087973A1/es unknown
- 2012-09-21 TW TW101134800A patent/TWI461435B/zh not_active IP Right Cessation
- 2012-09-25 PH PH1/2014/500740A patent/PH12014500740A1/en unknown
- 2012-09-25 BR BR112014007532A patent/BR112014007532A2/pt not_active IP Right Cessation
- 2012-09-25 WO PCT/US2012/057053 patent/WO2013052311A1/en not_active Ceased
- 2012-09-25 US US13/626,308 patent/US8541369B2/en active Active
- 2012-09-25 PE PE2014000472A patent/PE20142044A1/es not_active Application Discontinuation
- 2012-09-25 CN CN201280048530.2A patent/CN103906530B/zh not_active Expired - Fee Related
- 2012-09-25 EP EP12766847.3A patent/EP2763689B1/en active Active
- 2012-09-25 KR KR1020147008644A patent/KR20140059271A/ko not_active Withdrawn
- 2012-09-25 IN IN782CHN2014 patent/IN2014CN00782A/en unknown
- 2012-09-25 AU AU2012318956A patent/AU2012318956A1/en not_active Abandoned
- 2012-09-25 SG SG11201401792UA patent/SG11201401792UA/en unknown
- 2012-09-25 ES ES12766847.3T patent/ES2548214T3/es active Active
- 2012-09-25 EA EA201490521A patent/EA201490521A1/ru unknown
- 2012-09-25 CA CA2843520A patent/CA2843520A1/en not_active Abandoned
- 2012-09-25 MX MX2014004159A patent/MX2014004159A/es unknown
- 2012-09-25 AP AP2014007532A patent/AP2014007532A0/xx unknown
- 2012-09-25 JP JP2014534596A patent/JP6060167B2/ja active Active
-
2013
- 2013-08-13 US US13/965,243 patent/US8883726B2/en active Active
-
2014
- 2014-01-30 IL IL230754A patent/IL230754A0/en unknown
- 2014-02-05 ZA ZA2014/00882A patent/ZA201400882B/en unknown
- 2014-03-06 DO DO2014000050A patent/DOP2014000050A/es unknown
- 2014-03-06 TN TNP2014000096A patent/TN2014000096A1/en unknown
- 2014-03-17 CO CO14057034A patent/CO6910165A2/es unknown
- 2014-03-27 CR CR20140142A patent/CR20140142A/es unknown
- 2014-03-27 MA MA36861A patent/MA35458B1/fr unknown
- 2014-04-02 CL CL2014000801A patent/CL2014000801A1/es unknown
- 2014-04-04 EC ECSP14013285 patent/ECSP14013285A/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1890371A (zh) * | 2003-12-10 | 2007-01-03 | 伊莱利利公司 | 成纤维细胞生长因子的21突变蛋白 |
| CN101010338A (zh) * | 2004-09-02 | 2007-08-01 | 伊莱利利公司 | 成纤维细胞生长因子21的突变蛋白 |
| CN102143758A (zh) * | 2008-06-04 | 2011-08-03 | 安姆根有限公司 | Fgf21突变体及其用途 |
| WO2010065439A1 (en) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
Non-Patent Citations (1)
| Title |
|---|
| 定点突变FGF21提高表达量研究;李德山等;《东北农业大学学报》;20130331;第44卷(第3期);83-88 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103906530B (zh) | 成纤维细胞生长因子21变体 | |
| CN104364261B (zh) | 成纤维细胞生长因子21变体 | |
| CN104394882B (zh) | 成纤维细胞生长因子21蛋白 | |
| CN1346369B (zh) | 用于预防和治疗贫血的方法以及组合物 | |
| JP2007531715A (ja) | グリコール結合ｆｇｆ−２１化合物 | |
| WO2014149699A1 (en) | Bifunctional protein | |
| EP4059512A1 (en) | Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone | |
| EP4047006A1 (en) | Method for producing fusion protein of serum albumin and growth hormone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20180925 |